Chicago Fire give sneak peek at renderings for new stadium at The 78 in the South Loop
Chicago Fire release renderings of new stadium at The 78
Chicago Fire release renderings of new stadium at The 78
Chicago Fire release renderings of new stadium at The 78
The Chicago Fire released a sneak peek at renderings of the new stadium they're building in the South Loop.
The $650 million digs will be built along the Chicago River at The 78, a vacant plot of land south of Roosevelt Road. It will be privately funded by club owner Joe Mansueto and hold up to 22,000 fans.
The design is an ode to the warehouses that represent the city of Chicago's grit. Construction is set to begin early in 2026 and the club hopes to have the stadium open to fans by 2028.
CBS News Chicago spoke with club president Dave Baldwin about the decision to build in the South Loop.
"It was important for our owner Joe that it was inside the city," Baldwin said.
He said Mansueto fell in love with The 78 site, its accessibility and proximity to public transit, and how it was build-ready, with utilities in place.
"Then Joe started thinking about how he wanted to acquire the land and Joe ultimate decided to take this himself," Baldwin said.
Currently, the Chicago Fire host their games at Soldier Field.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
13 minutes ago
- Associated Press
Hall of Famer Dale Earnhardt Jr. wins NASCAR national series debut as crew chief at Pocono
LONG POND, Pa. (AP) — Dale Earnhardt Jr. might already be NASCAR's most popular crew chief. He's certainly an undefeated one. Pressed into unexpected service, Earnhardt called the shots for 18-year-old prospect Connor Zilisch in the No. 88 Chevrolet and they landed in victory lane Saturday in the second-tier Xfinity Series race at Pocono Raceway. 'We had a lot of things going our way,' Earnhardt said. Earnhardt — who won NASCAR's most-popular driver award 15 times — made a pit stop from his day job as team owner at JR Motorsports with normal crew chief Mardy Lindley suspended one race because of a lug nut infraction this month at Nashville. Aside from his duties as team owner, Earnhardt also was at Pocono for his role on the Prime broadcast for the NASCAR Cup Series race Sunday. 'Lot of fun for me today,' Earnhardt said. 'I missed the thrill of competition. I love broadcast, don't get me wrong. But nothing compares to driving or just being part of the team. Being an owner doesn't really deliver like this. This is a lot of fun.' Earnhardt had his wife and two young daughters in tow with him as he made the celebratory walk to victory lane. Oldest daughter Isla Rose clutched the checkered flag while youngest Nicole Lorraine soaked in the scene from her dad's arms. The win continued a banner season for the NASCAR Hall of Fame driver — who swept two races at Pocono as a driver in 2014 — after JR Motorsports and reigning Xfinity Series champion Justin Allgaier qualified for the season-opening Daytona 500 and secured their Cup Series debut. Earnhardt won two Daytona 500s, in 2004 and 2014, and 26 races overall. His side hustle Saturday was made a bit easier with Zilisch behind the wheel. Zilisch, who turns 19 in July, raced to his second Xfinity victory of the season and third of his young career. He won his Xfinity debut last year at Watkins Glen International. Earnhardt even pitched in during the race and tossed tires over the wall during pit stops. Zilisch took the win down to the wire and finally passed Jesse Love with five laps left in the race. Love finished second. 'Dale Junior, not too bad on the box,' Zilisch said. 'Pretty cool to have him up there. Getting him a 1-for-1 win as crew chief is pretty awesome.' ___ AP auto racing:
Yahoo
17 minutes ago
- Yahoo
NHL Free Agency: Top Six Pending UFA Centers
The NHL's free-agency period is almost here, and it's time to look at the key pivots who could be UFAs on July 1. has already looked at the top eight UFA defensemen and the top seven wingers. As for the centers, this is a rather thin class, but there's no doubt which center will be paid the most as a UFA this summer. 1. Sam Bennett, Florida Panthers Bennett was arguably the biggest impact player of the 2025 playoffs, winning the Conn Smythe Trophy as the MVP. Advertisement Bennett posted an amazing 15 goals and 22 points in 23 playoff games. No other player had more than 11 goals, making Bennett's scoring prowess all the more remarkable. The 29-year-old will get a massive raise on the $4.425 million he earned for the past four years. The Panthers aren't devoid of salary cap space, with $19 million in room. However, they might prioritize re-signing UFA winger Brad Marchand and defenseman Aaron Ekblad, cutting ties with Bennett and sending him to the open market looking for a bigger payday than Florida can afford. There will be a slew of teams – including the Toronto Maple Leafs, Boston Bruins, Columbus Blue Jackets, New York Rangers, Detroit Red Wings, Los Angeles Kings and many more – who will happily bring Bennett on board with a salary north of $8 million. It's all up to Bennett to choose where he plays next, but he can rest assured he'll be one of the most targeted assets in free agency. Gary Bettman presents Sam Bennett with the Conn Smythe Trophy. (Sam Navarro-Imagn Images) 2. John Tavares, Toronto Maple Leafs At 34 years old, Tavares is entering the final stage of his tremendous NHL career. But he hasn't let up in terms of offensive production, putting up 38 goals – his best total since 2018-19 – and 74 points in 75 games. There are few players more consistent as a point-per-game producer than Tavares, but he'll be taking a huge pay cut as he does his best to remain with his hometown Maple Leafs. Advertisement Thus, Tavares will be earning far less than the $11 million he earned for the past seven years. Rumored projections have him in the $4-million to $5-million range over a four- or five-year contract term. That should make Leafs fans very happy. Tavares can be part of the solution in Toronto by accepting a massive pay cut and allow the Buds to put together a deeper, stronger roster. 3. Mikael Granlund, Dallas Stars Very quietly, Granlund put together an excellent season, generating 44 assists and 66 points in 83 games split between the Stars and San Jose Sharks. In the playoffs, Granlund amassed another five goals and 10 points in 18 games with Dallas. He was a terrific acquisition, and he guaranteed himself a strong market for his services this summer. Granlund earned $5 million annually for the past six years, but at 33 years old, his next contract will likely be for three or four years. He'll probably want to sign on a bona fide Cup contender, but a developing team might offer him more money to come in and provide leadership and offensive consistency to their lineup. Regardless, once Bennett and Tavares come off the board, Granlund will quickly garner major attention and sign very soon on July 1. 4. Pius Suter, Vancouver Canucks For the first four years of his NHL career, Suter posted either 14 or 15 goals. But in 2024-25, he had a career-high 25 goals and 46 points in 81 games. The 29-year-old's agent had to be ecstatic with the timeliness of Suter's offensive outburst, because he's going to be the focus of teams that lose out on Bennett, Tavares and Granlund. Advertisement Suter was a serious bargain this year in particular, earning just $1.6 million. He'll easily double that amount this summer, as many teams – including the Canucks, which have the cap space to bring him back to Vancouver – will be jockeying for Suter's attention. We'll see who winds up with him, but there's no question he'll be in high demand. NHL Free Agency: Top Seven Pending UFA Wingers NHL Free Agency: Top Seven Pending UFA Wingers The NHL's free-agency period is fast approaching, so it's time to break down the key free agents who will soon be on the open market. 5. Christian Dvorak, Montreal Canadiens Dvorak has had trouble staying healthy, as he appeared in 82 games this past season for the first time in his nine-year NHL career. But as a third-line center option, he's going to be intriguing. Advertisement Dvorak posted 12 goals and 33 points last season – numbers that don't knock your socks off but aren't anything to sneer at, either. He won't match or better his 2024-25 salary of $4.45 million, but on a playoff-bound team, he could be a nifty little acquisition who is hungry and determined to be part of a winning organization. 6. Adam Gaudette, Ottawa Senators In parts of seven NHL seasons, the 28-year-old Gaudette has had to scratch and claw for opportunities in hockey's best league. Before this past season, his career high in games played was 59, back in 2019-20. But in '24-25, the Senators took a chance on him for just $775,000, and in return, Gaudette put up 19 goals and 26 points. So, once the other players on this list have signed a new contract, Gaudette is bound to get multiple offers for his services. The Sens aren't swimming in cap space, so Gaudette could be moving on to a different team next year. But as a third- or fourth-line option, he could fit in very well with a team intent on being a playoff contender. Get the latest news and trending stories by following The Hockey News on Google News and by subscribing to The Hockey News newsletter here. And share your thoughts by commenting below the article on
Yahoo
18 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
